Literature DB >> 23677958

Clinical and radiological outcomes of the Ivory arthroplasty for trapeziometacarpal joint osteoarthritis with a minimum of 5 years of follow-up: a prospective single-centre cohort study.

J F Goubau1, C K Goorens, P Van Hoonacker, B Berghs, D Kerckhove, T Scheerlinck.   

Abstract

We present the results of a 5 year prospective follow-up study on the functional outcome after total replacement of the trapeziometacarpal joint with the Ivory prosthesis (Memometal, Stryker Corporate, Kalamazoo, Michigan, USA) in 22 patients. The female to male ratio was 21:1 and the mean age was 66 (range 54-78) years. The mean follow-up period was 67 (range 60-77) months after operation. Patient satisfaction was high. The mobility of the operated thumb was restored to a range of motion comparable to the contralateral thumb. Key pinch and grip strength improved by 13% and 31%, respectively. Overall function, according to Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) score, improved by 59%. Pain decreased by 85% according to the numerical rating scale. Radiological evaluation revealed no loosening of the implant after 5 years except in one patient who required revision due to polythene wear with secondary joint instability. Another patient had asymptomatic polythene wear that required no revision but remains in follow-up. The 5 year overall survival of the prosthesis was 95%. These medium-term results suggest that the Ivory arthroplasty is a reliable option for treating advanced trapeziometacarpal arthritis, because it appears to give a very good functional outcome and has the potential for long-term survival rates.

Entities:  

Keywords:  Ivory prosthesis; Trapeziometacarpal arthroplasty; trapeziometacarpal arthritis

Mesh:

Year:  2013        PMID: 23677958     DOI: 10.1177/1753193413488494

Source DB:  PubMed          Journal:  J Hand Surg Eur Vol        ISSN: 0266-7681


  8 in total

1.  Retrospective Study of a Series of 20 Ivory Prostheses in the Treatment of Trapeziometacarpal Osteoarthritis.

Authors:  Anne J Spaans; L Paul van Minnen; Marieke E Weijns; Assa Braakenburg; Aebele B Mink van der Molen
Journal:  J Wrist Surg       Date:  2016-01-15

2.  De Quervain Tenosynovitis Following Trapeziometacarpal Ball-and-Socket Joint Replacement.

Authors:  Jean F Goubau; Laurent Goubau; Chul Ki Goorens; Petrus van Hoonacker; Diederick Kerckhove; Bert Vanmierlo; Bart Berghs
Journal:  J Wrist Surg       Date:  2015-02

3.  Arthrodesis of the Carpometacarpal Thumb Joint for Osteoarthritis; Long-Term Results Using Patient-Reported Outcome Measurements.

Authors:  Cecile M C A van Laarhoven; Verena J M M Schrier; Mark van Heijl; Arnold H Schuurman
Journal:  J Wrist Surg       Date:  2019-08-08

4.  Ivory Arthroplasty for Trapeziometacarpal Joint Arthritis in Men: Analysis of Clinical Outcome and Implant Survival.

Authors:  Bert Vanmierlo; John Buitenweg; Tim Vanmierlo; Kjell Van Royen; Francis Bonte; Jean Goubau
Journal:  Hand (N Y)       Date:  2020-07-22

5.  Treatment of the trapeziometacarpal osteoarthritis by arthroplasty with a pyrocarbon implant.

Authors:  Sergio Russo; Alessio Bernasconi; Gennaro Busco; Francesco Sadile
Journal:  Int Orthop       Date:  2015-10-23       Impact factor: 3.075

Review 6.  Developments in trapezium Replacements.

Authors:  Adam E M Eltorai; Alex Han
Journal:  Orthop Rev (Pavia)       Date:  2017-10-03

7.  Tendon versus Pyrocarbon Interpositional Arthroplasty in the Treatment of Trapeziometacarpal Osteoarthritis.

Authors:  Won-Taek Oh; Yong-Min Chun; Il-Hyun Koh; Jong-Kwan Shin; Yun-Rak Choi; Ho-Jung Kang
Journal:  Biomed Res Int       Date:  2019-07-22       Impact factor: 3.411

8.  Total arthroplasty with Ivory® prosthesis versus resection-suspension arthroplasty: a retrospective cohort study on 82 carpometacarpal-I osteoarthritis patients over 4 years.

Authors:  Stefan M Froschauer; Matthias Holzbauer; Richard F Schnelzer; Manfred Behawy; Oskar Kwasny; Matthias M Aitzetmüller; Hans-Günther Machens; Dominik Duscher
Journal:  Eur J Med Res       Date:  2020-04-15       Impact factor: 2.175

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.